# Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.

> **NCT02000453** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 2 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** GSK2586184 400mg

## Key facts

- **NCT ID:** NCT02000453
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12-20
- **Primary completion:** 2014-08-08
- **Final completion:** 2014-08-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** GSK has elected to terminate development principally as a result of the statin drug-drug interaction (DDI) study.
- **Last updated:** 2020-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000453, "Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02000453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*